{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:29:28Z","timestamp":1789662568947,"version":"4.0.1"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008666","name":"Marathon Foundation of Tv3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espana Ministerio de Ciencia e Innovacion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Government of Catalonia Agency for Administration of University and Research Grants","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundacion Cientifica de la Asociacion Espaoola Contra el Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phymed.2026.158481","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:38:00Z","timestamp":1782373080000},"page":"158481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Silibinin is a natural molecular glue that inhibits PD-L1 glycomaturation"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-3218","authenticated-orcid":false,"given":"Eduard","family":"Teixidor-Vil\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Encinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Martin-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Lupu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0893-7821","authenticated-orcid":false,"given":"Joaquim","family":"Bosch-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-4561","authenticated-orcid":false,"given":"Javier A.","family":"Menendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-0423","authenticated-orcid":false,"given":"Sara","family":"Verdura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5353-440X","authenticated-orcid":false,"given":"Elisabet","family":"Cuy\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2026.158481_bib0001","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/ptr.3207","article-title":"Milk thistle in liver diseases: past, present, future","volume":"24","author":"Abenavoli","year":"2010","journal-title":"Phytother. Res."},{"key":"10.1016\/j.phymed.2026.158481_bib0002","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/ptr.6171","article-title":"Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases","volume":"32","author":"Abenavoli","year":"2018","journal-title":"Phytother. Res."},{"key":"10.1016\/j.phymed.2026.158481_bib0003","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ccell.2024.12.008","article-title":"A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer","volume":"43","author":"Acha-Sagredo","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phymed.2026.158481_bib0004","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest."},{"key":"10.1016\/j.phymed.2026.158481_bib0005","article-title":"Neoadjuvant chemoradiotherapy up-regulates PD-L1 in radioresistant colorectal cancer","volume":"51","author":"Bae","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.phymed.2026.158481_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.chembiol.2025.05.005","article-title":"Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation","volume":"32","author":"Baro","year":"2025","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.phymed.2026.158481_bib0007","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1039\/C3NP70122K","article-title":"Chemistry of silybin","volume":"31","author":"Biedermann","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.phymed.2026.158481_bib0008","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3390\/molecules22111942","article-title":"Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)-chemistry, bioavailability, and metabolism","volume":"22","author":"Bijak","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.phymed.2026.158481_bib0009","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"Cancer immunology. The \"cancer immunogram\"","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.phymed.2026.158481_bib0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ctrv.2015.04.008","article-title":"Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy","volume":"41","author":"Bosch-Barrera","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phymed.2026.158481_bib0011","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2017.06.003","article-title":"Targeting STAT3 with silibinin to improve cancer therapeutics","volume":"58","author":"Bosch-Barrera","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phymed.2026.158481_bib0012","doi-asserted-by":"crossref","first-page":"32006","DOI":"10.18632\/oncotarget.7900","article-title":"Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin","volume":"7","author":"Bosch-Barrera","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phymed.2026.158481_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1612327","article-title":"The STAT3\/TIMP1 inhibitor silibinin overcomes secondary immunoresistance to pembrolizumab in brain metastases from METex14 skipping mutated non-small cell lung cancer: a case report","volume":"12","author":"Bosch-Barrera","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.phymed.2026.158481_bib0014","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.3390\/cancers13164168","article-title":"Silibinin suppresses tumor cell-intrinsic resistance to nintedanib and enhances its clinical activity in lung cancer","volume":"13","author":"Bosch-Barrera","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phymed.2026.158481_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.899192","article-title":"Nascent glycoproteome reveals that N-linked glycosylation inhibitor-1 suppresses expression of glycosylated lysosome-associated membrane protein-2","volume":"9","author":"Cao","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.phymed.2026.158481_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13205","article-title":"Research progress of PD-L1 non-glycosylation in cancer immunotherapy","volume":"96","author":"Cao","year":"2022","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.phymed.2026.158481_bib0017","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phymed.2026.158481_bib0018","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phymed.2026.158481_bib0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","article-title":"Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion","volume":"430","author":"Chaganty","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2026.158481_bib0020","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"5","author":"Chen","year":"2014","journal-title":"Nat Commun."},{"key":"10.1016\/j.phymed.2026.158481_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1831153","article-title":"Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export","volume":"9","author":"Chen","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.phymed.2026.158481_bib0022","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.phymed.2026.158481_bib0023","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/carcin\/bgab063","article-title":"Inhibition of GFAT1 in lung cancer cells destabilizes PD-L1 protein","volume":"42","author":"Chen","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.phymed.2026.158481_bib0024","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2112258118","article-title":"PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage","volume":"118","author":"Cheon","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phymed.2026.158481_bib0025","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.canlet.2016.06.023","article-title":"Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells","volume":"380","author":"Coombs","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2026.158481_bib0026","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1080\/15384101.2016.1245249","article-title":"STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer","volume":"15","author":"Cuy\u00e0s","year":"2016","journal-title":"Cell. Cycle"},{"key":"10.1016\/j.phymed.2026.158481_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110645","article-title":"Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: computational modeling and experimental validation","volume":"132","author":"Cuy\u00e0s","year":"2019","journal-title":"Food. Chem. Toxicol."},{"key":"10.1016\/j.phymed.2026.158481_bib0028","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-022-05375-7","article-title":"High-potency PD-1\/PD-L1 degradation induced by peptide-PROTAC in human cancer cells","volume":"13","author":"Dai","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phymed.2026.158481_bib0029","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1055\/s-0032-1328703","article-title":"A rapid and simple chromatographic separation of diastereomers of silibinin and their oxidation to produce 2,3-dehydrosilybin enantiomers in an optically pure form","volume":"79","author":"Di Fabio","year":"2013","journal-title":"Planta Med."},{"key":"10.1016\/j.phymed.2026.158481_bib0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.cell.2018.10.037","article-title":"Structures of DPAGT1 explain glycosylation disease mechanisms and advance TB antibiotic design","volume":"175","author":"Dong","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.phymed.2026.158481_bib0031","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12967-024-05502-2","article-title":"N-linked glycosylation of PD-L1\/PD-1: an emerging target for cancer diagnosis and treatment","volume":"22","author":"Duan","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phymed.2026.158481_bib0032","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/v12050525","article-title":"Potential drugs targeting early innate immune evasion of SARS-coronavirus 2 via 2\u2032-O-methylation of viral RNA","volume":"12","author":"Encinar","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.phymed.2026.158481_bib0033","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-018-0022-9","article-title":"The intracellular signalosome of PD-L1 in cancer cells","volume":"3","author":"Escors","year":"2018","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phymed.2026.158481_bib0034","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/ph17030316","article-title":"A comprehensive computational insight into the PD-L1 binding to PD-1 and small molecules","volume":"17","author":"Fantacuzzi","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.phymed.2026.158481_bib0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/molecules22020191","article-title":"Silymarin\/silybin and chronic liver disease: a marriage of many years","volume":"22","author":"Federico","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.phymed.2026.158481_bib0036","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48826-6","article-title":"Comprehensive in vitro characterization of PD-L1 small molecule inhibitors","volume":"9","author":"Ganesan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phymed.2026.158481_bib0037","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.phymed.2026.158481_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189274","article-title":"Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies","volume":"1880","author":"Granica","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.phymed.2026.158481_bib0039","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phymed.2026.158481_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1022129","article-title":"Regulation of IFN-\u03b3-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications","volume":"13","author":"Guo","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.phymed.2026.158481_bib0041","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.3390\/ijms22094766","article-title":"Molecular mechanism of small-molecule inhibitors in blocking the PD-1\/PD-L1 pathway through PD-L1 dimerization","volume":"22","author":"Guo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010924","article-title":"Molecular mechanism of food-derived polyphenols on PD-L1 dimerization: a molecular dynamics simulation study","volume":"22","author":"Guo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0043","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-molecule inhibitors of the programmed cell death-1\/programmed death-ligand 1 (PD-1\/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1","volume":"60","author":"Guzik","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phymed.2026.158481_bib0044","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1158\/0008-5472.CAN-22-1060","article-title":"The \"inside\" story on tumor-expressed PD-L1","volume":"82","author":"Hanks","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2026.158481_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/srep35297","article-title":"High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1","volume":"6","author":"Horita","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phymed.2026.158481_bib0046","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","article-title":"Posttranslational modifications of PD-L1 and their applications in cancer therapy","volume":"78","author":"Hsu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2026.158481_bib0047","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","article-title":"STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion","volume":"9","author":"Hsu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2026.158481_bib0048","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158481_bib0049","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12943-025-02330-w","article-title":"N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1","volume":"24","author":"Kaufman","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2026.158481_bib0050","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.7150\/thno.99562","article-title":"Silybin A from Silybum marianum reprograms lipid metabolism to induce a cell fate-dependent class switch from triglycerides to phospholipids","volume":"15","author":"Koeberle","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.phymed.2026.158481_bib0051","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1002\/anie.201710407","volume":"57","author":"Konstantinidou","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.phymed.2026.158481_bib0052","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phymed.2026.158481_bib0053","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.3390\/ijms22157885","article-title":"Chirality matters: biological activity of optically pure silybin and Its congeners","volume":"22","author":"K\u0159en","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0054","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.3390\/cancers15092638","article-title":"Design and biological evaluation of small-molecule PET-tracers for imaging of programmed death ligand 1","volume":"15","author":"Krutzek","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.phymed.2026.158481_bib0055","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1038\/s41598-017-06002-8","article-title":"Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phymed.2026.158481_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217498","article-title":"Regulation of PD-L1 glycosylation and advances in cancer immunotherapy","volume":"612","author":"Lee","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2026.158481_bib0057","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1158\/2326-6066.CIR-22-0953","article-title":"Regulation of PD-L1 trafficking from synthesis to degradation","volume":"11","author":"Lemma","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.phymed.2026.158481_bib0058","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phymed.2026.158481_bib0059","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2026.158481_bib0060","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/ijms24021280","article-title":"Approaching the dimerization mechanism of small molecule inhibitors targeting PD-L1 with molecular simulation","volume":"24","author":"Liang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2026.158481_bib0062","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2026.158481_bib0063","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers : the \"all-around warrior\" in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2026.158481_bib0064","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/1878-0261.12664","article-title":"Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma","volume":"14","author":"Liu","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.phymed.2026.158481_bib0065","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nchembio.2194","article-title":"Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells","volume":"12","author":"Lopez-Sambrooks","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phymed.2026.158481_bib0066","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.3390\/molecules25225293","article-title":"Virtual screening and in vitro evaluation of PD-1 dimer stabilizers for uncoupling PD-1\/PD-L1 interaction from natural products","volume":"25","author":"Lung","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.phymed.2026.158481_bib0067","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature23669","article-title":"Identification of CMTM6 and CMTM4 as PD-L1 protein regulators","volume":"549","author":"Mezzadra","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.phymed.2026.158481_bib0068","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1263412","article-title":"The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200","volume":"6","author":"Noman","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.phymed.2026.158481_bib0069","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","article-title":"Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis","volume":"185","author":"Pan","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.phymed.2026.158481_bib0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1158\/2159-8290.CD-24-0134","article-title":"TIMP1 mediates astrocyte-dependent local immunosuppression in brain metastasis acting on infiltrating CD8+ T cells","volume":"15","author":"Priego","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phymed.2026.158481_bib0071","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41591-018-0044-4","article-title":"STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis","volume":"24","author":"Priego","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.phymed.2026.158481_bib0072","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","article-title":"The diverse function of PD-1\/PD-L pathway beyond cancer","volume":"10","author":"Qin","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2026.158481_bib0073","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phymed.2026.158481_bib0074","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.chembiol.2018.07.005","article-title":"Editing N-glycan site occupancy with small-molecule oligosaccharyltransferase inhibitors","volume":"25","author":"Rinis","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.phymed.2026.158481_bib0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/ijms19020563","article-title":"Regulation of programmed death ligand 1 (PD-L1) expression in breast cancer cell lines in vitro and in immunodeficient and humanized tumor mice","volume":"19","author":"Rom-Jurek","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0076","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/cells10071632","article-title":"Silibinin regulates tumor progression and tumorsphere formation by suppressing PD-L1 expression in non-small cell lung cancer (NSCLC) cells","volume":"10","author":"Rugamba","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.phymed.2026.158481_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.114826","article-title":"JAK\/STAT-mediated regulation of PD-L1 expression in breast cancer: molecular mechanisms and implications for immunotherapy","volume":"29","author":"Sang","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.phymed.2026.158481_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.752065","article-title":"Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced development","volume":"13","author":"Sasikumar","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.phymed.2026.158481_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108479","article-title":"Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism","volume":"690","author":"Sellam","year":"2020","journal-title":"Arch Biochem. Biophys."},{"key":"10.1016\/j.phymed.2026.158481_bib0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.phymed.2026.158481_bib0081","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/jnci\/djj231","article-title":"Effect of silibinin on the growth and progression of primary lung tumors in mice","volume":"98","author":"Singh","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.phymed.2026.158481_bib0082","doi-asserted-by":"crossref","first-page":"72167","DOI":"10.18632\/oncotarget.20050","article-title":"Small-molecule inhibitors of PD-1\/PD-L1 immune checkpoint alleviate the PD- L1-induced exhaustion of T-cells","volume":"8","author":"Skalniak","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phymed.2026.158481_bib0083","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.phymed.2026.158481_bib0084","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3390\/ijms26031238","article-title":"Glycoscience in advancing PD-1\/PD-L1-axis-targeted tumor immunotherapy","volume":"26","author":"Sun","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0085","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.phymed.2026.158481_bib0086","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/1940-6207.CAPR-08-0095","article-title":"Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3","volume":"2","author":"Tyagi","year":"2009","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.phymed.2026.158481_bib0087","doi-asserted-by":"crossref","first-page":"8","DOI":"10.18632\/aging.102646","article-title":"Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity","volume":"12","author":"Verdura","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.phymed.2026.158481_bib0088","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.fct.2018.04.028","article-title":"Silibinin is a direct inhibitor of STAT3","volume":"116","author":"Verdura","year":"2018","journal-title":"Food. Chem. Toxicol."},{"key":"10.1016\/j.phymed.2026.158481_bib0089","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1633235","article-title":"Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy","volume":"8","author":"Verdura","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.phymed.2026.158481_bib0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/ph14060559","article-title":"Lung cancer management with silibinin: a historical and translational perspective","volume":"14","author":"Verdura","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.phymed.2026.158481_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155493","article-title":"Silibinin is a suppressor of the metastasis-promoting transcription factor ID3","volume":"128","author":"Verdura","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2026.158481_bib0092","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.3390\/cancers14246101","article-title":"Silibinin overcomes EMT-driven lung cancer resistance to new-generation ALK inhibitors","volume":"14","author":"Verdura","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.phymed.2026.158481_bib0093","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/eji.200535387","article-title":"TCR-independent cytokine stimulation induces non-MHC-restricted T cell activity and is negatively regulated by HLA class I","volume":"36","author":"von Geldern","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.phymed.2026.158481_bib0094","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41419-022-05090-3","article-title":"N-glycosylation of GDF15 abolishes its inhibitory effect on EGFR in AR inhibitor-resistant prostate cancer cells","volume":"13","author":"Wang","year":"2022","journal-title":"Cell. Death Dis."},{"key":"10.1016\/j.phymed.2026.158481_bib0095","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1021\/acs.jmedchem.3c02143","article-title":"Reducing PD-L1 expression by degraders and downregulators as a novel strategy to target the PD-1\/PD-L1 pathway","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phymed.2026.158481_bib0096","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41467-021-27781-9","article-title":"Mammalian brain glycoproteins exhibit diminished glycan complexity compared to other tissues","volume":"13","author":"Williams","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2026.158481_bib0097","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cbi.2014.01.004","article-title":"Silibinin induces apoptosis of HT29 colon carcinoma cells through early growth response-1 (EGR-1)-mediated non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) up-regulation","volume":"211","author":"Woo","year":"2014","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.phymed.2026.158481_bib0098","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-020-0366-x","article-title":"Small molecule inhibitors targeting the PD-1\/PD-L1 signaling pathway","volume":"42","author":"Wu","year":"2021","journal-title":"Acta. Pharmacol Sin."},{"key":"10.1016\/j.phymed.2026.158481_bib0099","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/ijms24021413","article-title":"Is the triggering of PD-L1 dimerization a potential mechanism for food-derived small molecules in cancer immunotherapy? A study by molecular dynamics","volume":"24","author":"Wu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0100","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 Distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.phymed.2026.158481_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.130921","article-title":"Computational analysis of PD-L1 dimerization mechanism induced by small molecules and potential dynamical properties","volume":"265","author":"Xu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.phymed.2026.158481_bib0101","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41368-024-00311-1","article-title":"Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma","volume":"16","author":"Xu","year":"2024","journal-title":"Int. J. Oral. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0103","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phymed.2026.158481_bib115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.lungcan.2013.09.019","article-title":"Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer","volume":"83","author":"Yamaguchi","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phymed.2026.158481_bib0104","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phymed.2026.158481_bib0105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/ijms19020340","article-title":"Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T","volume":"19","author":"Yoon","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158481_bib0106","doi-asserted-by":"crossref","first-page":"30323","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phymed.2026.158481_bib0107","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.phymed.2026.158481_bib0108","doi-asserted-by":"crossref","first-page":"19216","DOI":"10.1021\/acs.jmedchem.4c01652","article-title":"Advancing cancer immunotherapy through engineering new PD-L1 degraders: a comprehensive study from small molecules to PD-L1-specific peptide-drug conjugates","volume":"67","author":"Zeng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phymed.2026.158481_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116267","article-title":"Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents","volume":"268","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phymed.2026.158481_bib0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117867","article-title":"Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1\/PD-L1 interaction","volume":"111","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phymed.2026.158481_bib0111","article-title":"Role of regulation of PD-1 and PD-L1 expression in sepsis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2026.158481_bib0112","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-025-02411-w","article-title":"Advances and obstacles of T cell-based immunotherapy in gynecological malignancies","volume":"24","author":"Zhao","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2026.158481_bib0113","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/molecules24101940","article-title":"The characteristics of PD-L1 inhibitors, from peptides to small molecules","volume":"24","author":"Zhong","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.phymed.2026.158481_bib0114","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s42003-022-03845-4","article-title":"Homodimerized cytoplasmic domain of PD-L1 regulates its complex glycosylation in living cells","volume":"5","author":"Zhou","year":"2022","journal-title":"Commun. Biol."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711326007129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711326007129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:45:09Z","timestamp":1785509109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711326007129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":115,"alternative-id":["S0944711326007129"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2026.158481","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Silibinin is a natural molecular glue that inhibits PD-L1 glycomaturation","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2026.158481","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"158481"}}